101/194US=2 / Tórax
Pisters KMW. Induction chemotherapy for resectable lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 233-46. ISBN 978-1-4051-5112-2.

QUIMIOTERAPIA DE INDUCAO; CANCER DE PULMAO RESSECAVEL

102/194US=2 / Tórax
Rosenzwei KE, Sura S. Image-guided radiation therapy. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 247-54. ISBN 978-1-4051-5112-2.

IMAGEM DE RADIOTERAPIA GUIADA; PET; PET-CT; IMAGEM DE RADIOTERAPIA GUIADA

103/194US=2 / Tórax
Timmerman RD, Kavanagh BD. Stereotactic body radiation therapy for lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 256-70. ISBN 978-1-4051-5112-2.

RADIOTERAPIA ESTEREOTAXICA NO CORPO. CANCER DE PULMAO; HISTORIA DE SBRT

104/194US=2 / Tórax
Chang JY, Smith AR, Cox JD. Proton therapy. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 271-82. ISBN 978-1-4051-5112-2.

PROTON TERAPIA; PROTONS. TRATAMENTO; MOVIMENTO TUMOR

105/194US=2 / Tórax
Liao Z, Fossella FV, Komaki R. Combinations of radiation and chemotherapy for nonsmall cell lung carcinoma. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 283-314. ISBN 978-1-4051-5112-2.

COMBINACOES DE RADIACAO; CARCINOMA DE PULMAO DE CELULAS NONSMALL. QUIMIOTERAPIA; QUIMIOTERAPIA; RADIOTERAPIA CONCOMITANTE

106/194US=2 / Tórax
Tsao AS. New chemotherapeutic agents in lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 315-333. ISBN 978-1-4051-5112-2.

AGENTES QUIMIOTERAPICOS NO CANCER DE PULMAO; CANCER DE PULMAO

107/194US=2 / Tórax
Lee JM, Dubinett SM, Sharma S. Immunological approaches to lung cancer therapy. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 334-51. ISBN 978-1-4051-5112-2.

TRATAMENTO DE CANCER DE PULMAO; VIGILANCIA DO CANCER IMUNE; IMMUNOEDITING CANCER; IMUNOSSUPRESSAO; IMUNOTERAPIA DO CANCER

108/194US=2 / Tórax
Sequist LV, Lynch TJ. Epidermal growth factor receptor inhibitors. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 352-68. ISBN 978-1-4051-5112-2.

CRESCIMENTO EPIDERMICO; RECEPTOR INIBIDORES DO FACTOR

109/194US=2 / Tórax
Hanrahan EO, Nilsson M, Heymach JV. Tumor angiogenesis: biology and therapeutic implications for lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 369-85. ISBN 978-1-4051-5112-2.

ANGIOGENESE TUMORAL; TERAPEUTICA PARA O CANCER DE PULMAO; ANGIOGENESE NO CANCER DE PULMAO

110/194US=2 / Tórax
Bhadkamkar NA, Khuri FR. Retinoids and rexinoids in lung cancer prevention and treatment. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 386-98. ISBN 978-1-4051-5112-2.

RETINOIDES; REXINOIDES; CANCER DE PULMAO. PREVENCAO; CANCER DE PULMAO. TRATAMENTO

111/194US=2 / Tórax
Huynh M, Lara PN Jr. Proteasome inhibition in nonsmall cell lung cancer therapy. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 400-10. ISBN 978-1-4051-5112-2.

INIBICAO DO PROTEASSOMA EM NAO PEQUENA; TERAPIA DE CANCER DE PULMAO DE CELULAS

112/194US=2 / Tórax
Roth JA. Targeted genetic therapy for lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 411-20. ISBN 978-1-4051-5112-2.

TERAPIA GENETICA; CANCER DE PULMAO. TERAPIA

113/194US=2 / Tórax
Mulshine JL. Screening for early detection. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 421-40. ISBN 978-1-4051-5112-2.

TRIAGEM PARA A DETECCAO PRECOCE; RASTREIO DO CANCER DO PULMAO

114/194US=2 / Tórax
Sharafkhaneh A, Velamuri S, Moghaddam SJ, Badmaev V, Dickey B, Kurie J. Natural agents for chemoprevention of lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung cancer. 3rd ed. Oxford: Blackwell Science, 2008. p. 441-55. ISBN 978-1-4051-5112-2.

QUIMIOPREVENCAO DO CANCER DE PULMAO; CANCER DE PULMAO

115/194US=433 / Tese/FAP
Costa AC. Impacto da expressão de fatores relacionados a hipóxia (HIF1A e VEGF) e metabolismo lipídico (LXRA, LXRB e PPARG) em tumores de cólon estádio clínico II e III). [Impact of expression of factors related to hypoxia (HIF1A and VEGF) and lipid metabolism (LXRA, LXRB and PPARG) in colon cancer clinical stage II and III]. São Paulo, 2012. 80 p. Dissertação(Mestrado)-Fundação Antônio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2012/AdrianoCarneiro/AdrianoCarneiro.pdf

Curriculum Lattes

NEOPLASIAS DO COLO; CANCER DE COLON; HIPOXIA; FATOR 1 INDUZIVEL POR HIPOXIA; FATORES DE CRESCIMENTO DO ENDOTELIO VASCULAR; LIPIDEOS. METABOLISMO

116/194US=65 / Biol/Mol
Cox JH, Overall CM. Cytokine substrates: MMP regulation of inflammatory signaling molecules. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 519-39. ISBN 978-0-387-69056-8.

SUBSTRATOS DE CITOCINAS; MMP; REGULACAO DE MOLECULAS; SINALIZACAO INFLAMATORIAS; INFLAMACAO; QUIMIOCINAS

117/194US=67 / Biol/Mol
Bertagnolli M, Viner JL, Hawk ET. Cyclooxygenase-2 as a target for cancer prevention and treatment. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 509-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4.

CICLOOXIGENASE-2; COX-2; CANCER. PREVENCAO; CANCER. TRATAMENTO; INFLAMACAO; PROSTAGLANDINA; TUMORIGENESE

118/194US=90 / Biol/Mol
Dannenberg AJ, Subbaramaiah K. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: crosstalk between COX-2 and EGFR: apontential therapeutic opportunity. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 337-51. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

CICLOOXIGENASE-2; PROSTAGLANDINAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; CROSSTALK; CANCER

119/194US=90 / Biol/Mol
Buck E, Eyzaguirre A, Iwata KK. EGFR in tumorigenesis and EGFR tyrosine kinase inhibitors in cancer therapy: utilizing combination of molecular targeted agents to sensitize tumor cells to EGFR inhibitors. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 369-82. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

EMT; TRANSICAO EPITELIAL MESENQUIMAL; ERLOTINIB; EGFR; IGF-1R; ER; HER3; MTOR; HDAC; SRC; COX-2

120/194US=23 / Clín/Médica
Curi R, Bittencourt Junior PH. Aspectos imunológicos: reconhecimento e ataque ao antígeno: metabolismo do ácido araquidônico. In: Silva FP, Velasco IT. Sepse. Barueri: Manole, 2007. p. 214-42. ISBN 85-2042558-5.

ACIDO ARAQUIDONICO; PRODUCAO DE EICOSANOIDES; CICLOXIGENASE (COX); LIPOXIGENASE (LOX); ISOPROSTANAS; LEVUGLANDINA; ISOLEVUGLANDINA; CATABOLISMO; SISTEMA NERVOSO CENTRAL; SISTEMA VARDIOVASCULAR; SISTEMA DIGESTIVO; SISTEMA ENDOCRINO; SISTEMA REPRODUTOR; SISTEMA RESPIRATORIO; SISTEMA URINARIO

Primeira | Anterior | Próxima | Última